Evidence map›Paper›PMID 39623194›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

The role of curcumin in modulating circular RNAs and long non-coding RNAs in cancer.

Hamidreza Rismanchi, Mohaddese Malek Mohammadi, Alireza Mafi, Parisa Khalilzadeh, Najma Farahani, Sepideh Mirzaei, Hossein Khorramdelazad, Behnaz Mahmoodieh, Payman Rahimzadeh, Mina Alimohammadi and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hamidreza Rismanchi *School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohaddese Malek Mohammadi *School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Alireza MafiNutrition and Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Parisa KhalilzadehDepartment of Clinical Biochemistry, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Najma FarahaniFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Sepideh MirzaeiDepartment of Biology, Faculty of Science, Islamic Azad University, Science and Research Branch, Tehran, Iran.
Hossein KhorramdelazadDepartment of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Behnaz MahmoodiehYoung Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. behi_mahmodieh@yahoo.com.
Payman RahimzadehSurgical Research Society (SRS), Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran. P.rahimzadeh76@gmail.com.
Mina AlimohammadiDepartment of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. mina.alimohammadi@sbmu.ac.ir.ORCID http://orcid.org/0000-0002-5953-3894
Pooyan MakvandiThe Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, 324000, China. pooyanmakvandi@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is one of the primary causes of human disease and death, with high morbidity and mortality rates. Chemotherapy, one of the most common therapeutic techniques, functions through a variety of mechanisms, including the production of apoptosis and the prevention of tumor development. Herbal medicine has been the subject of numerous investigations due to its potential as a valuable source of innovative anti-cancer products that target multiple protein targets and cancer cell genomes. Curcumin, a polyphenol that is the major bioactive ingredient of turmeric, exhibits pharmacological and biological efficacy with antioxidant, anti-inflammatory, anticancer, cardioprotective, neuroprotective, and hypoglycemic activity in humans and animals. Recent research suggests that curcumin changes noncoding RNA (ncRNA), such as long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs), in various types of cancers. Both circRNAs and lncRNAs are ncRNAs that can epigenetically modulate the expression of multiple genes via post-transcriptional regulation. In this study, we outline curcumin's activities in modulating signaling pathways and ncRNAs in various malignancies. We also described curcumin's regulatory function, which involves blocking carcinogenic lncRNAs and circRNAs while increasing tumor-suppressive ones. Furthermore, we intend to demonstrate how ncRNAs and signaling pathways interact with each other across regulatory boundaries to gain a better understanding of how curcumin fights cancer and create a framework for its potential future therapeutic uses.

Indexed as

Antineoplastic AgentsCurcuminNeoplasmsRNARNA, CircularRNA, Long NoncodingAnimalsGene Expression Regulation, NeoplasticHumansSignal TransductionAntineoplastic AgentsCurcuminRNARNA, CircularRNA, Long NoncodingCancercircRNAsCurcuminlncRNAsSignaling pathways

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.